OncoBay Clinical Announces Vice President of Clinical Operations
Leading immunotherapy-focused contract research organization
announces Dannelle Palmer as key contributor on the executive team.
TAMPA, Fla. (June 30, 2020) — OncoBay Clinical, Inc., a full-service boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, is pleased to announce the appointment of Dannelle Palmer as Vice President of Clinical Operations.
Palmer is a results-driven, quality-oriented and creative executive bringing to OncoBay over 20 years of global clinical development experience in pharmaceuticals and biotechnologies within global CRO organizations. Her expertise and experience ranges from clinical development planning and regulatory consulting to leading studies from first in human through U.S. Food and Drug Administration and European Medicines Agency approval. For the past 13 years, she has held executive level positions focused on portfolio leadership, strategic leadership and customer relationship development.
“I am delighted to have an executive of Dannelle’s caliber and experience join our executive team,” said Krystyna Kowalczyk, president and CEO of OncoBay. “Her track record of successfully leading clinical research teams with an emphasis on enhancing the performance and efficiency of oncology clinical research will be instrumental to the execution of our vision and continued growth and success.”
In her role, Palmer will be responsible for the development and implementation of OncoBay’s clinical and project management infrastructure and oversight of project teams working in the comprehensive clinical technology ecosystem. Additionally, she will assume responsibility for the continued growth and oversight of OncoBay’s site networks including the OncoBay Cell Therapy Consortium and the OncoBay Immune-Oncology (IO) Network. These specialized networks increase patient access, reduce time and decrease the expense required to conduct clinical trials.
“I am excited to join OncoBay Clinical’s leadership team and take on this critically important role. Our clinical technology infrastructure combined with our site networks will solidify our position as a leader in the IO and cell therapy CRO space,” said Palmer.
To learn more about OncoBay Clinical, please visit www.OncoBay.com.
About OncoBay Clinical
OncoBay Clinical is a boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, offering full- service custom-curated CRO solutions for global pharmaceutical and biotech companies looking to advance their immuno-oncology product or device. As a wholly owned, for-profit subsidiary of Moffitt Cancer Center, OncoBay embeds scientific expertise, operational excellence and integrated cell manufacturing capabilities providing true end-to-end control. Built on years of IO and cell therapy expertise, a streamlined technology framework, a highly trained site network, and a dedicated team of experienced professionals, OncoBay is committed to operational excellence from start to finish. For more information, visit OncoBay.com and follow us on Facebook, Twitter and LinkedIn.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 6,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
OncoBay Clinical, Vice-President Business Operations